In particular, several presentations outlined the effects of VISTA blockade, including a decrease in myeloid suppression of immune responses coupled with proinflammatory changes in the tumor microenvironment (TME) by mechanisms separate and distinct from PD-1 and CTLA-4 inhibition. The gene discussed is VSIR; the disease is neoplasm.